NERV News and Press, Minerva Neurosciences Inc From 12/28/22

BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on Novem...

Palm Beach, FL – November 14, 2022 – FinancialNewsMedia.com News Commentary – Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to relieve anxiety and tension, work by reducing the symptoms of anxiety, such as f...

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Conference Call November 9, 2022 08:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas...

Minerva Neurosciences press release ( NASDAQ: NERV ): Q3 GAAP EPS of -$1.29 beats by $0.03 . Cash, cash equivalents and restricted cash as of September 30, 2022 were approximately $40.3 million, compared to $60.9 million as of December 31, 2021. The Company expects...

BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results ...

BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results an...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Short-squeeze stocks continue to be a big deal for speculative traders and we’re helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Sque...

Updated to add the share move after the trading halt. Minerva Neurosciences ( NASDAQ: NERV ), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a t...

Minerva Neurosciences ( NASDAQ: NERV ), a biotech focused on central nervous system diseases, announced Monday that the FDA issued a "refusal to file" letter regarding its marketing application for roluperidone, a treatment targeted at schizophrenia patients. Without detai...

BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the company has received a refusal to...